Johnson & Johnson (JNJ) Long-Term Deferred Tax (2009 - 2026)
Johnson & Johnson (JNJ) posted Long-Term Deferred Tax of $6.7 billion for Q2 2026, little changed sequentially from $6.7 billion in Q1 2026, and down 1.07% YoY from $6.8 billion in Q2 2025.
Johnson & Johnson (JNJ) Long-Term Deferred Tax (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Long-Term Deferred Tax for 18 years, with the latest figure at $6.7 billion in Q2 2026.
- Quarterly Long-Term Deferred Tax fell 1.07% year-over-year to $6.7 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $6.7 billion (down 1.07% YoY) and the FY2025 annual result came in at $6.9 billion, down 34.29% from the prior year.
- Long-Term Deferred Tax steadied at $6.7 billion in Q2 2026 per JNJ's latest filing, from $6.7 billion in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $10.5 billion in Q4 2024 and troughed at $6.7 billion in Q3 2025.
- A 5-year average of $8.7 billion and a median of $9.0 billion in 2024 frame the typical range for Long-Term Deferred Tax.
- The sharpest annual moves came in 2022 and 2025: Long-Term Deferred Tax rose 19.79% in 2022, then tumbled 34.29% in 2025.
- Over 5 years, Long-Term Deferred Tax stood at $9.4 billion in 2022, then dropped by 1.2% to $9.3 billion in 2023, then gained by 12.74% to $10.5 billion in 2024, then sank by 34.29% to $6.9 billion in 2025, then declined by 2.12% to $6.7 billion in 2026.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $6.7 billion, $6.7 billion, and $6.9 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 6.73 Bn |
| Mar 29, 2026 | 6.73 Bn |
| Dec 28, 2025 | 6.87 Bn |
| Sep 28, 2025 | 6.67 Bn |
| Jun 29, 2025 | 6.80 Bn |
| Mar 30, 2025 | 8.49 Bn |
| Dec 29, 2024 | 10.46 Bn |
| Sep 29, 2024 | 9.35 Bn |
| Jun 30, 2024 | 9.00 Bn |
| Mar 31, 2024 | 10.31 Bn |
| Dec 31, 2023 | 9.28 Bn |
| Oct 1, 2023 | 9.26 Bn |
| Jul 2, 2023 | 8.78 Bn |
| Apr 2, 2023 | 8.82 Bn |
| Jan 1, 2023 | 8.95 Bn |
| Oct 2, 2022 | 9.39 Bn |
| Jul 3, 2022 | 9.51 Bn |
| Apr 3, 2022 | 9.94 Bn |
| Jan 2, 2022 | 10.22 Bn |
| Oct 3, 2021 | 10.65 Bn |